Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection

New England Journal of Medicine

Volumn 352, Issue 6, 2005, Pages 558-569

  Dragun, Duska ^a,b   Müller, Dominik N ^d   Bräsen, Jan Hinrich ^c   Fritsche, Lutz ^a   Nieminen Kelhä, Melina ^a,b   Dechend, Ralf ^c   Kintscher, Ulrich ^b   Rudolph, Birgit ^a   Hoebeke, Johan ^f   Eckert, Diana ^a   Mazak, Istvan ^c   Plehm, Ralph ^d   Schönemann, Constanze ^e   Unger, Thomas ^b   Budde, Klemens ^a   Neumayer, Hans Hellmut ^a   Luft, Friedrich C ^c   Wallukat, Gerd ^d  

^a Department of Nephrology ^*  (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c FRANZ VOLHARD CLINIC   (Germany)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^e Tissue Typing Laboratory   (Germany)

^f CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DNA; EPITOPE; HLA ANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; INTERLEUKIN 2 RECEPTOR ANTIBODY; LOSARTAN; METHYLPREDNISOLONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THROMBOPLASTIN; TRANSCRIPTION FACTOR AP 1;

ADOLESCENT; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MALIGNANT HYPERTENSION; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN DNA BINDING; RAT; RENOVASCULAR HYPERTENSION; SEIZURE; VASCULAR DISEASE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AUTOANTIBODIES; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; FEMALE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; HYPERTENSION; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY; KIDNEY TRANSPLANTATION; LOSARTAN; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PLASMAPHERESIS; RATS; RATS, INBRED F344; RATS, INBRED LEW; RECEPTOR, ANGIOTENSIN, TYPE 1; TRANSCRIPTION FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 13444267698     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa035717     Document Type: Article

References (38)

1. van Saase J, van der Woude FJ, Thorogood J, et al. The relation between acute vascular and interstitial renal allograft rejection and subsequent chronic rejection. Transplantation 1995;59:1280-5.
2. Jeannet M, Pinn VW, Flax MH, Winn HJ, Russell PS. Humoral antibodies in renal allotransplantation in man. N Engl J Med 1970;282:111-7.
3. Ahern AT, Artruc SB, DellaPelle P, et al. Hyperacute rejection of HLA-AB-identical renal allografts associated with B lymphocytes and endothelial reactive antibodies. Transplantation 1982;33:103-6.
4. Yard B, Spruyt-Gerritse M, Claas F, et al. The clinical significance of allospecific antibodies against endothelial cells detected with an antibody-dependent cellular cytotoxicity assay for vascular rejection and graft loss after renal transplantation. Transplantation 1993;55:1287-93.
5. Le Bas-Bernardet S, Hourmant M, Coupel S, Bignon JD, Soulillou JP, Charreau B. Non-HLA-type endothelial cell reactive alloantibodies in pre-transplant sera of kidney recipients trigger apoptosis. Am J Transplant 2003;3:167-77.
6. Mellor AL, Munn DH. Immunology at the maternal-fetal interface: lessons for T cell tolerance and suppression. Annu Rev Immunol 2000;18:367-91.
7. Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic antibodies against the angiotensin AT1 receptor. J Clin Invest 1999;103:945-52.
8. Dragun D, Bräsen JH, Schönemann C, et al. Patients with steroid refractory acute vascular rejection develop agonistic antibodies targeting angiotensin II type 1 receptor. Transplant Proc 2003;35:2104-5.
9. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999;55:713-23.
10. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003;3:708-14.
11. Böhmig G, Exner M, Habicht A, et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002;13:1091-9.
12. Regele H, Exner M, Watschinger B, et al. Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol Dial Transplant 2001;16:2058-66.
13. Wallukat G, Wollenberger A, Morwinski R, Pitschner HF. Anti-β1-adrenoreceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops. J Mol Cell Cardiol 1995;27:397-406. [Erratum, J Mol Cell Cardiol 1995;27:2529.]
14. Dechend R, Homuth V, Wallukat G, et al. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation 2000;101:2382-7.
15. Dragun D, Hoff U, Park JK, et al. Ischemia-reperfusion injury in renal transplantation is independent of the immunologic background. Kidney Int 2000;58:2166-77.
16. Baeuerle P. IκB-NF-κB structures: at the interface of inflammation control. Cell 1998;95:729-31.
17. Thway TM, Shlykov SG, Day MC, et al. Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation. Circulation 2004;110:1612-9.
18. Magnusson Y, Wallukat G, Waagstein F, Hjalmarson A, Hoebeke J. Autoimmunity in idiopathic dilated cardiomyopathy: characterization of antibodies against the beta1-adrenoceptor with positive chronotropic effect. Circulation 1994;89:2760-7.
19. Fu ML, Herlitz H, Wallukat G, et al. Functional autoimmune epitope on α1-adrenergic receptors in patients with malignanthypertension. Lancet 1994;344:1660-3.
20. Rapaport B, McLachlan SM. Thyroid autoimmunity. J Clin Invest 2001;108:1253-9.
21. Paul LC, Baldwin WM III, van Es LA. Vascular endothelial alloantigens in renal transplantation. Transplantation 1985;40:117-23.
22. van der Woude FJ, Deckers JGM, Mallat MJK, et al. Tissue antigens in tubulointerstitial and vascular rejection. Kidney Int 1995; 52:Suppl:S11-S13.
23. Praprotnik S, Blank M, Meroni PL, Rozman B, Eldor A, Shoenfeld Y. Classification of anti-endothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells: the pathogenic and diagnostic implications. Arthritis Rheum 2001;44:1484-94.
24. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International Union of Pharmacology: XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415-72.
25. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J. Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 2001;10:321-9.
26. Vos IH, Govers S, Gröne HJ, et al. NF-κB decoy oligodeoxynucleotides reduce monocyte infiltration in renal allografts. FASEB J 2000;14:815-22.
27. Heidenreich S, Dercken C, August C, Koch HG, Nowak-Göttl U. High rate of acute rejections in renal allograft recipients with thrombophilic risk factors. J Am Soc Nephrol 1998;9:1309-13.
28. Dobado-Berrios P, Lopez-Pedrera C, Velasco F, Cuadrado MJ. The role of tissue factor in the antiphospholipid syndrome. Arthritis Rheum 2001;44:2467-76.
29. Hölschermann H, Bohle RM, Zeller H, et al. In situ detection of tissue factor within the coronary intima in rat cardiac graft vasculopathy. Am J Pathol 1999;154:211-20.
30. Hisada Y, Sugaya T, Yamanouchi M, et al. Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice. J Clin Invest 1999;103:627-35.
31. Nataraj C, Oliverio M, Mannon RB, et al. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest 1999;104:1693-701.
32. Shimada K, Yazaki Y. Binding sites for angiotensin II in human mononuclear leucocytes. J Biochem (Tokyo) 1978;84:1013-5.
33. Nahmod KA, Vermeulen ME, Raiden S, et al. Control of dendritic cell differentiation by angiotensin II. FASEB J 2003;17:491-3.
34. Mauiyyedi S, Crespo M, Collins AB, et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002;13:779-87.
35. Schwimmbeck PL, Dyrberg T, Drachman DB, Oldstone MB. Molecular mimicry and myasthenia gravis: an autoantigenic site of the acetylcholine receptor α-subunit that has biologic activity and reacts immunochemically with herpes simplex virus. J Clin Invest 1989;84:1174-80.
36. Masuda MO, Levin M, De Oliveira SF, et al. Functionally active cardiac antibodies in chronic Chagas' disease are specifically blocked by Trypanosoma cruzi antigens. FASEB J 1998;12:1551-8.
37. Miller JA, Thai K, Scholey JW. Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int 1999;56:2173-80.
38. Remuzzi G, Perico N. Routine renin-angiotensin system blockade in renal transplantation? Curr Opin Nephrol Hypertens 2002;11:1-10.